U.S. Bancorp stock flirts with a 52-week high as bond sale and Fed week come into view
23 January 2026
1 min read

U.S. Bancorp stock flirts with a 52-week high as bond sale and Fed week come into view

New York, Jan 22, 2026, 20:18 EST — Market closed

  • Shares of U.S. Bancorp climbed 1.28% on Thursday, closing close to their 52-week peak
  • The bank issued $1.25 billion in fixed-to-floating senior notes maturing in 2032
  • The Fed’s Jan. 27-28 meeting stands as the next major trigger for bank stock movements

Shares of U.S. Bancorp (USB) climbed 1.28% to $56.18 on Thursday, marking a second consecutive gain and closing just shy of a 52-week high. The day’s trading volume more than doubled the 50-day average. USB outperformed Bank of America but fell short of Wells Fargo, as U.S. equities wrapped up the session higher. 1

The bank remains locked near its highs heading into Friday, a precarious position where even minor rate changes could trigger significant swings. For bank stocks, the coming week hinges on yields and funding.

U.S. Bancorp, a major regional lender with a strong payments and fee business, often serves as a gauge for deposit competition trends. Investors watch it closely, as its shares can react more to shifts in rate expectations than to the news itself.

A filing with the Securities and Exchange Commission dated Jan. 21 revealed the company priced $1.25 billion in fixed-to-floating senior notes maturing in 2032, due to settle on Jan. 26. The notes carry a 4.481% coupon through 2031. After that, the rate shifts to compounded SOFR — a key U.S. money-market benchmark — plus 86.7 basis points, or 0.867 percentage points. 2

U.S. Bancorp posted a 23% surge in fourth-quarter profit to $2.05 billion, or $1.26 per share, on Tuesday. The boost came from higher interest income and increased fee revenue. Net interest income climbed 3.3% to $4.28 billion, while fees rose 7.6% to $3.05 billion. The bank projects revenue growth of 4% to 6% in 2026, excluding BTIG, which it plans to acquire for up to $1 billion. 3

The bank reported a net interest margin of 2.77%—the gap between loan earnings and deposit costs—and a common equity tier 1 capital ratio of 10.8% at year-end, according to its earnings filing with regulators. CEO Gunjan Kedia noted that “fee income exceeded our mid-single-digit growth target.” The filing also detailed a cross-border stablecoin pilot, testing a crypto token pegged to hold steady value. 4

Stocks trading near their highs don’t require much negative news to wobble. A sharper fall in market rates or fresh pressure on deposit pricing could tighten margins, and a shift in the credit cycle would push charge-offs higher.

Investors are turning their attention to the Federal Reserve’s policy meeting on Jan. 27-28, with the rate statement and press conference scheduled for Jan. 28. A change in the Fed’s outlook on inflation or growth could swiftly impact bank stocks, including U.S. Bancorp. 5

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts
Previous Story

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Datadog stock jumps 6% after Stifel upgrade as investors brace for Feb. earnings and NYC investor day
Next Story

Datadog stock jumps 6% after Stifel upgrade as investors brace for Feb. earnings and NYC investor day

Go toTop